Skip to main content

The Office of Cancer Genomics – Building resources for precision cancer medicine

Friday, November 08, 2013 — Poster Session III

10:00 a.m. – 12:00 p.m.

FAES Academic Center (Upper-Level Terrace)




  • E.J. Gillespie
  • S. Behrman
  • M.J. Stine
  • J.M. Guidry Auvil
  • M. Ferguson
  • J.C. Zenklusen
  • D.S. Gerhard


The Office of Cancer Genomics (OCG), within the National Cancer Institute, supports cutting-edge genomics and translational research to advance the understanding of cancer at the molecular level, with the ultimate goal of improving clinical outcomes. Through its cancer research initiatives, OCG generates comprehensive molecular characterization datasets for multiple cancer types and shares these results with the community to expedite their translation to the clinic. OCG currently supports three collaborative and innovative initiatives: 1. The Cancer Genome Characterization Initiative (CGCI) utilizes advanced genomic sequencing technologies to molecularly characterize selected cancer types, such as lymphoid and HIV-associated cancers. 2. The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative uses genome-wide approaches to identify candidate therapeutic targets and biomarkers in high-risk childhood cancer patients. These findings will be used to develop more effective treatments. 3. The Cancer Target Discovery and Development (CTD2) Network combines high-throughput computational and functional approaches to accelerate translation of genomic discoveries into new patient-specific cancer treatments. Data and resources generated by OCG initiatives are made publicly available through the OCG website, There you can also learn about valuable scientific resources from completed OCG initiatives, such as the Cancer Genome Anatomy Project and the Mammalian Gene Collection.

back to top